Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: pyxisoncology.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/21/2024 | Outperform → Mkt Perform | William Blair | |
| 11/8/2024 | $13.00 | Overweight | Stephens |
| 8/8/2024 | $10.00 | Buy | Stifel |
| 5/7/2024 | $10.00 | Buy | Jefferies |
| 2/9/2024 | $8.00 | Buy | BTIG Research |
| 1/23/2024 | $12.00 | Outperform | Leerink Partners |
| 9/5/2023 | $7.00 | Outperform | RBC Capital Mkts |
| 11/2/2021 | $16.00 | Neutral | B of A Securities |
| 11/2/2021 | $25.00 | Buy | Jefferies |
| 11/2/2021 | $19.00 | Outperform | Credit Suisse |
8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)
8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
SCHEDULE 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)
DEFA14A - Pyxis Oncology, Inc. (0001782223) (Filer)
DEF 14A - Pyxis Oncology, Inc. (0001782223) (Filer)
144 - Pyxis Oncology, Inc. (0001782223) (Subject)
144 - Pyxis Oncology, Inc. (0001782223) (Subject)
144 - Pyxis Oncology, Inc. (0001782223) (Subject)
SCHEDULE 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)